Prognostic value of pretreatment platelet and fibrinogen levels for early non-small cell lung cancer after complete resection
10.3969/j.issn.1000-8179.2018.05.178
- VernacularTitle:术前血小板及血浆纤维蛋白原对早期非小细胞肺癌的预后价值
- Author:
Yuchen MA
1
;
Hua ZHANG
;
Bin ZHANG
;
Changli WANG
Author Information
1. 天津医科大学肿瘤医院肺部肿瘤科
- Keywords:
platelets;
fibrinogen;
prognosis;
neoplasm metastasis;
non-small-cell lung cancer
- From:
Chinese Journal of Clinical Oncology
2018;45(5):222-227
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the prognostic value of pretreatment platelet and fibrinogen levels for non-small cell lung cancer (NSCLC)after complete resection.Methods:Four hundred and five patients with pathological-proven NSCLC who underwent complete resection between March 2004 and January 2007 were included in this study.Blood samples for pretreatment platelet and fibrinogen examinations were collected.Platelet and fibrinogen levels were analyzed with patients'clinical parameters.Results:The overall preva-lence of thrombocytosis(>350×109/L)was 16.5%,and that of hyperfibrinogenemia(>4 g/L)was 36.3%.Patients with thrombocytosis and/or hyperfibrinogenemia exhibited poor overall survival(P=0.002).Multivariate survival analysis using the Cox proportional hazard model demonstrated that pretreatment platelet levels(P=0.048),tumor stage(P<0.05),and tumor progression(P<0.05)were indepen-dent prognostic factors of NSCLC.The median survival time among patients with low-,intermediate-,and high-risk NSCLC were 67,24, and 20 months, respectively (P<0.05). Conclusions: Elevated pretreatment platelet and fibrinogen levels significantly correlate with poor survival in patients with NSCLC.Moreover,the risk model can potentially improve prognosis by enabling the detection of high-risk patients and providing a reference for individualized treatments.
